CA2340322A1 - Dnazymes and methods for treating restenosis - Google Patents

Dnazymes and methods for treating restenosis Download PDF

Info

Publication number
CA2340322A1
CA2340322A1 CA002340322A CA2340322A CA2340322A1 CA 2340322 A1 CA2340322 A1 CA 2340322A1 CA 002340322 A CA002340322 A CA 002340322A CA 2340322 A CA2340322 A CA 2340322A CA 2340322 A1 CA2340322 A1 CA 2340322A1
Authority
CA
Canada
Prior art keywords
dnazyme
restenosis
myc
onset
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002340322A
Other languages
English (en)
French (fr)
Inventor
Lun-Quan Sun
Murray J. Cairns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Research Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2340322A1 publication Critical patent/CA2340322A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
CA002340322A 1998-08-13 1999-08-12 Dnazymes and methods for treating restenosis Abandoned CA2340322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9637498P 1998-08-13 1998-08-13
US60/096,374 1998-08-13
PCT/IB1999/001484 WO2000009672A1 (en) 1998-08-13 1999-08-12 Dnazymes and methods for treating restenosis

Publications (1)

Publication Number Publication Date
CA2340322A1 true CA2340322A1 (en) 2000-02-24

Family

ID=22257071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340322A Abandoned CA2340322A1 (en) 1998-08-13 1999-08-12 Dnazymes and methods for treating restenosis

Country Status (8)

Country Link
EP (1) EP1117768A4 (ko)
JP (1) JP2002525037A (ko)
KR (1) KR20010072475A (ko)
CN (1) CN1323344A (ko)
AU (1) AU5298499A (ko)
CA (1) CA2340322A1 (ko)
WO (1) WO2000009672A1 (ko)
ZA (1) ZA200101188B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ201499A0 (en) * 1999-08-04 1999-08-26 Unisearch Limited Treatment of inflammatory and malignant diseases
JP2002348235A (ja) * 2001-03-23 2002-12-04 Clinical Supply:Kk 再狭窄予防剤
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
WO2007000676A2 (en) * 2005-06-28 2007-01-04 Johnson & Johnson Research Pty. Ltd. Guanosine-rich oligonucleotides as agents for inducing cell death in eukaryotic cells
SI3093022T1 (sl) 2015-05-15 2019-12-31 Sterna Biologicals Gmbh & Co. Kg GATA-3 inhibitorji za uporabo pri zdravljenju astme, ki jo povzroča TH2
WO2022146868A1 (en) * 2020-12-30 2022-07-07 The Regents Of The University Of California A biologically stable xnazyme that efficiently silences gene expression in cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
DE69429087T2 (de) * 1993-01-07 2002-07-11 Thomas Jefferson University Ph Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
CN1261920A (zh) * 1997-04-29 2000-08-02 斯克里普斯研究学院 酶促dna分子
CA2312288A1 (en) * 1998-03-27 1999-10-07 Johnson & Johnson Research Pty. Limited Catalytic nucleic acid-based diagnostic methods

Also Published As

Publication number Publication date
JP2002525037A (ja) 2002-08-13
WO2000009672A9 (en) 2000-05-18
WO2000009672A1 (en) 2000-02-24
CN1323344A (zh) 2001-11-21
KR20010072475A (ko) 2001-07-31
AU5298499A (en) 2000-03-06
ZA200101188B (en) 2002-05-13
EP1117768A1 (en) 2001-07-25
EP1117768A4 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
US5646042A (en) C-myb targeted ribozymes
US7662948B2 (en) Antisense oligonucleotides against VR1
EP1251170A2 (en) Method and reagent for treatment of NF-kappaB dependent animal diseases
US5866699A (en) Oligonucleotides with anti-MDR-1 gene activity
US6103890A (en) Enzymatic nucleic acids that cleave C-fos
WO1998032846A9 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
AU3974001A (en) Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
CA2340322A1 (en) Dnazymes and methods for treating restenosis
US5714383A (en) Method and reagent for treating chronic myelogenous leukemia
CA2148687A1 (en) Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US20040072783A1 (en) Nucleozymes with endonuclease activity
AU3497701A (en) Nucleozymes with endonuclease activity
JP2002526072A (ja) 遺伝子発現の調節のためのヘアピンハイブリダイザー分子
EP2327784A2 (en) Nucleic acids for inhibiting hairless protein expression and methods of use thereof
US6238917B1 (en) Asymmetric hammerhead ribozymes
AU721758B2 (en) Asymmetric hammerhead ribozymes
WO2002011674A2 (en) Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
WO2001062911A2 (en) Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses
Phylactou et al. Utilization of properties of natural catalytic RNA to design and synthesize functional ribozymes
AU6879501A (en) Methods and compositions for treatment of restenosis and cancer using ribozymes
AU3918899A (en) Methods and compositions for treatment of restenosis and cancer using ribozymes
MXPA01002953A (en) Hairpin hybridizer molecules for modulation of gene expression
AU2005242129A1 (en) Catalytic molecules
WO2001034793A1 (en) Method of effecting dna splicing
AU5661700A (en) Method and reagent for treatment of animal diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued